FDA Drugs recall ·

Carvedilol Tablets USP 3.125mg Tablets a.)100-count bottle ( recall

Recall number
D-0448-2025
Date
(initiated February 28, 2025)
Company / brand
Glenmark Pharmaceuticals Inc., USA
750 Corporate Dr, Mahwah, NJ, United States
Category
Drugs › Class II
Classification
Class II
Status
Ongoing
Units affected
[100 Tablet Bottles] 59,952 bottles; [500 Tablet Bottles] 155,976 bottles
Hazard tags
Manufacturing practices (cGMP)
Initiated by
Voluntary: Firm initiated

Read the official FDA notice ↗

Product

Carvedilol Tablets USP 3.125mg Tablets a.)100-count bottle (NDC 68462-162-01), b.) 500-count bottle (NDC 68462-162-05), Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430.

Why was it recalled?

CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit

What should you do?

FDA enforcement reports do not list a consumer remedy. Check the product codes below against what you have; if it matches, stop using it and follow the instructions in the firm's or FDA's official notice, or contact the company. If you have health concerns, contact your healthcare provider.

Product codes & lot numbers

[100-Count Bottles] Lot 19231450, Exp Mar-25, 19233345, Exp Jul-25; Lot 19234275, Exp Sep-25; Lot 19240280, Exp DEC-25 [500-Count Bottles] Lot 19231450, 19231464, 19231471, 19231493, Exp Mar-25, 19232083, 19232103 Exp Apr-25, 19232658, Exp Jun-25; Lot 19233328, 19233343, 19233344, 19233345, Exp Jul-25; Lot 19234275, Exp Sep-25; Lots 19234843, 19235039, Exp Nov-25; Lots 19240280, 19240296, Dec-25

Distribution

U.S. Nationwide

What does Class II mean?

Class II means use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or the probability of serious harm is remote.

Source: FDA (drugs), recall D-0448-2025. Official notice. Republished from public data; RecallFlag is not affiliated with the FDA.